CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Novartis AG (NVS) / ianalumab
Forward catalyst · NVS

ianalumab

Sponsor Novartis AG · listed as NVS

READOUT Phase 3 Confidence: medium Source: clinicaltrials

ianalumab is a clinical-stage drug asset sponsored by Novartis AG, listed as NVS. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Mar 24, 2027 (day precision, medium confidence), tied to trial NCT05639114. The asset is in Phase 3 and currently active not recruiting, studied in Systemic Lupus Erythematosus. It appears across 4 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-03-24
As disclosedMar 24, 2027
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05639114
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorNovartis Pharmaceuticals
Listed asNVS
Condition(s)Systemic Lupus Erythematosus

All tracked catalysts for ianalumab

DateEventConfidenceTrial
2027-03-24READOUTmediumNCT05639114
2027-04-12READOUTmediumNCT05624749
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More NVS catalysts